This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Janni, W. Articles by Harbeck, N. Search for Related Content PubMed PubMed Citation Articles by Janni, W. Articles by Harbeck, N.

Detection of Micrometastatic Disease in Bone Marrow: Is It Ready for Prime Time?

^a Department of Obstetrics and Gynecology, Ludwig-Maximilians University, Munich, Germany; ^b Department of Obstetrics and Gynecology, Technical University of Munich, Munich, Germany

Correspondence: Nadia Harbeck, M.D., Department of Obstetrics and Gynecology, Technical University of Munich, Ismaninger Strasse 22, D-81675 Munich, Germany. Telephone: 49-89-4140-6658; Fax: 49-89-4140-4846; e-mail: nadia.harbeck{at}lrz.tum.de

Minimal residual disease (MRD), or isolated tumor cells (ITCs) in bone marrow, may be the source of potentially fatal overt distant metastases in solid tumors even years after primary treatment. MRD can be detected by immunohistochemical methods using antibodies directed against cytokeratins or cell-surface markers or molecular, polymerase chain reaction–based techniques. Among solid tumors, the clinical relevance of MRD has been most extensively studied in breast cancer patients. Recently, the highest level of evidence for the prognostic impact of MRD in primary breast cancer was reached by a pooled analysis comprising more than 4,000 patients, showing poor outcome in patients with MRD at primary therapy. Yet the clinical application of MRD detection is hampered by the lack of a standardized detection assay. Moreover, clinical trial results demonstrating the benefit of a therapeutic intervention determined by bone marrow status are still absent. Recent results suggest that, in addition to its prognostic impact, MRD can be used for therapy monitoring or as a potential therapeutic target after phenotyping of the tumor cells. Persistent MRD after primary treatment may lead to an indication for extended adjuvant therapy. However, until clinically relevant data regarding successful therapy of MRD are available, treatment interventions on the basis of MRD should only be performed within clinical trials.

Key Words. Micrometastasis • Breast cancer • Solid tumors • Prognosis • Minimal residual disease • Disseminated tumor cells • Isolated tumor cells

This article has been cited by other articles:

				K. Pachmann, O. Camara, A. Kavallaris, S. Krauspe, N. Malarski, M. Gajda, T. Kroll, C. Jorke, U. Hammer, A. Altendorf-Hofmann, et al. Monitoring the Response of Circulating Epithelial Tumor Cells to Adjuvant Chemotherapy in Breast Cancer Allows Detection of Patients at Risk of Early Relapse J. Clin. Oncol., March 10, 2008; 26(8): 1208 - 1215. [Abstract] [Full Text] [PDF]